Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 20511541)

1.

Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo.

Na IK, Markley JC, Tsai JJ, Yim NL, Beattie BJ, Klose AD, Holland AM, Ghosh A, Rao UK, Stephan MT, Serganova I, Santos EB, Brentjens RJ, Blasberg RG, Sadelain M, van den Brink MR.

Blood. 2010 Sep 16;116(11):e18-25. doi: 10.1182/blood-2009-12-259432. Epub 2010 May 28.

2.

Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.

Drobyski WR, Majewski D, Hanson G.

Biol Blood Marrow Transplant. 1999;5(4):222-30.

3.

IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.

Lu Y, Giver CR, Sharma A, Li JM, Darlak KA, Owens LM, Roback JD, Galipeau J, Waller EK.

Blood. 2012 Jan 26;119(4):1075-85. doi: 10.1182/blood-2010-12-322891. Epub 2011 Nov 30.

4.

APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease.

Zhang Y, Shlomchik WD, Joe G, Louboutin JP, Zhu J, Rivera A, Giannola D, Emerson SG.

J Immunol. 2002 Dec 15;169(12):7111-8.

5.

Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.

Wang J, Li L, Xu M, Rong R, Zhu T.

Transplantation. 2013 Nov 15;96(9):774-81. doi: 10.1097/TP.0b013e3182a1931f.

6.

Fas-deficient lpr mice are more susceptible to graft-versus-host disease.

van Den Brink MR, Moore E, Horndasch KJ, Crawford JM, Hoffman J, Murphy GF, Burakoff SJ.

J Immunol. 2000 Jan 1;164(1):469-80.

7.

Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo.

Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W, Finn R, Akhurst T, Larson S, Blasberg R, Sadelain M, Tjuvajev JG.

Neoplasia. 2001 Nov-Dec;3(6):480-8.

8.

The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model.

Dey B, Yang YG, Preffer F, Shimizu A, Swenson K, Dombkowski D, Sykes M.

Transplantation. 1999 Jul 15;68(1):141-9.

PMID:
10428282
9.

CD4-CD8-C.B-17 SCID thymocytes enter the CD4+CD8+ stage in the presence of neonatally grafted T cells.

Schneider MK, Grönvik KO.

Scand J Immunol. 1998 May;47(5):466-74.

PMID:
9627131
10.

Nuclear factor-kappaB inducing kinase is required for graft-versus-host disease.

Sánchez-Valdepeñas C, Casanova L, Colmenero I, Arriero M, González A, Lozano N, González-Vicent M, Díaz MA, Madero L, Fresno M, Ramírez M.

Haematologica. 2010 Dec;95(12):2111-8. doi: 10.3324/haematol.2010.028829. Epub 2010 Sep 7.

11.

The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning.

Gonzalez M, Quezada SA, Blazar BR, Panoskaltsis-Mortari A, Rudensky AY, Noelle RJ.

J Immunol. 2002 Nov 15;169(10):5581-9.

12.

Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.

Hossain MS, Jaye DL, Pollack BP, Farris AB, Tselanyane ML, David E, Roback JD, Gewirtz AT, Waller EK.

J Immunol. 2011 Nov 15;187(10):5130-40. doi: 10.4049/jimmunol.1101334. Epub 2011 Oct 17.

13.
14.
15.
16.

Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.

Sato M, Storb R, Loretz C, Stone D, Mielcarek M, Sale GE, Rezvani AR, Graves SS.

Transplantation. 2013 Jul 15;96(1):34-41. doi: 10.1097/TP.0b013e318295c025.

17.

Migration and activation of T cells during development of graft-versus-host disease in a mouse model.

Wen HS, Wang JM, Zhou H, Gong SI, Gao L, Wu Y.

Transplant Proc. 2013 Mar;45(2):713-8. doi: 10.1016/j.transproceed.2012.12.004.

PMID:
23498811
18.

Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.

Askenasy N, Mizrahi K, Ash S, Askenasy EM, Yaniv I, Stein J.

Biol Blood Marrow Transplant. 2013 Feb;19(2):185-95. doi: 10.1016/j.bbmt.2012.10.004. Epub 2012 Oct 16.

19.

Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation.

Ross D, Jones M, Komanduri K, Levy RB.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1430-8. doi: 10.1016/j.bbmt.2013.06.019. Epub 2013 Jun 29.

PMID:
23819914
20.

Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.

MacDonald KP, Rowe V, Filippich C, Thomas R, Clouston AD, Welply JK, Hart DN, Ferrara JL, Hill GR.

Blood. 2003 Mar 1;101(5):2033-42. Epub 2002 Oct 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk